18F-FDG乳腺正电子发射显像与全身18F-FDG PET评估乳腺癌新辅助化疗反应的前瞻性观察研究
前瞻性观察20例乳腺癌患者,在新辅助化疗前、2周期后及全部疗程后各行一次全身PET(WBPET)与乳腺正电子发射显像(PEM)。9例达病理完全缓解(pCR)。2周期后WBPET的SUVmax在pCR组显著低于非pCR组(1.4±0.4 vs 2.7±2.1,P=0.0334),PEM的PUVmax两组无显著差异;全部疗程后PUVmax在pCR组显著低于非pCR组(1.0±0.2 vs 2.5±2.7,P=0.0351)。
要点
- 2周期后WBPET的SUVmax预测非pCR的AUC为0.761,优于PUVmax的0.648。
- 全部疗程后PUVmax预测非pCR的AUC为0.796,优于WBPET的SUVmax的0.671。
- 作者结论:PEM在中期预测pCR方面无明显优势,全部疗程后检出残留癌的诊断能力更强。
核心结论
- 作者结论认为,PEM在中期时间点预测pCR方面没有明显优势,而在全部疗程新辅助化疗后对检出残留癌具有更强的诊断能力。
研究设计与样本
- 前瞻性观察研究,纳入20例乳腺癌患者,在新辅助化疗前、2周期后及全部疗程后各行一次WBPET与PEM检查。
- pCR定义为无残留浸润性癌证据,伴或不伴导管原位癌。
- 评估各模态SUVmax与病理反应的关系。
主要发现
- 9例达pCR,11例为非pCR。
- 2周期后WBPET的SUVmax在pCR组显著低于非pCR组:1.4±0.4 vs 2.7±2.1,P=0.0334。
- 2周期后PEM的PUVmax两组间无显著差异。
- 预测非pCR:2周期后WBPET的SUVmax的AUC为0.761,PUVmax的AUC为0.648。
- 全部疗程后两组WBPET的SUVmax无显著差异;PUVmax在pCR组显著低于非pCR组:1.0±0.2 vs 2.5±2.7,P=0.0351;PUVmax的AUC为0.796,WBPET的SUVmax的AUC为0.671。
关键数值与推荐
- pCR定义:无残留浸润性癌证据,伴或不伴导管原位癌。
- 2周期后预测非pCR:WBPET的SUVmax的AUC为0.761,PUVmax的AUC为0.648。
- 全部疗程后预测非pCR:PUVmax的AUC为0.796,WBPET的SUVmax的AUC为0.671。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to assess therapeutic response to breast cancer neoadjuvant chemotherapy (NAC) by F-FDG positron emission mammography (PEM) compared with that to whole-body F-FDG PET (WBPET). METHODS: Twenty patients underwent WBPET and PEM 3 times: the first time was before NAC, the second time was after 2 courses of NAC, and the third time was after all courses of NAC. A pathological complete response (pCR) was defined as no evidence of residual invasive cancer with or without ductal carcinoma in situ. The relationships between each modality's SUVmax and pathological response were evaluated. RESULTS: Nine patients achieved a pCR, whereas the other 11 patients had a non-pCR. The SUVmax of WBPET after 2 courses of NAC was significantly lower in the pCR group than in the non-pCR group (1.4 ± 0.4 vs 2.7 ± 2.1, P = 0.0334). There were no significant differences in the SUVmax of PEM (ie, PEM uptake value [PUV]) between the groups. The SUVmax of WBPET (area under the ROC curve [AUC] = 0.761) was superior to the PUVmax (AUC, 0.648) for predicting non-pCR at the interim time point. After all courses of chemotherapy, there were no significant differences between the groups in the SUVmax of WBPET; however, PUVmax was significantly lower in the pCR group than in the non-pCR group (1.0 ± 0.2 vs 2.5 ± 2.7, P = 0.0351). After NAC, the PUVmax (AUC, 0.796) was superior to the SUVmax of WBPET (AUC, 0.671). CONCLUSIONS: There proved to be no apparent superiority of PEM in predicting pCR at the interim time point. Positron emission mammography had greater diagnostic capability for detecting residual cancer after all courses of NAC.
引用
- Noritake M, Narui K, Kaneta T, et al. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study. Clin Nucl Med. 2017. PMID: 28072617. doi:10.1097/RLU.0000000000001497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。